Search Page

1

Cite

Share

Management of pregnant women with antiphospholipid antibodies.

Ruffatti A, Favaro M, Calligaro A, Zambon A, Del Ross T. Ruffatti A, et al. Among authors: calligaro a. Expert Rev Clin Immunol. 2019 Apr;15(4):347-358. doi: 10.1080/1744666X.2019.1565995. Epub 2019 Jan 11. Expert Rev Clin Immunol. 2019. PMID: 30616398 Review.

Cite

Share

2

Cite

Share

Thrombocytopenia in high-risk patients with antiphospholipid syndrome.

Pontara E, Banzato A, Bison E, Cattini MG, Baroni G, Denas G, Calligaro A, Marson P, Tison T, Ruffatti A, Pengo V. Pontara E, et al. Among authors: calligaro a. J Thromb Haemost. 2018 Mar;16(3):529-532. doi: 10.1111/jth.13947. Epub 2018 Jan 25. J Thromb Haemost. 2018. PMID: 29316193 Free article.

Cite

Share

3

Cite

Share

Are biological drugs safe in pregnancy?

Calligaro A, Hoxha A, Ruffatti A, Punzi L. Calligaro A, et al. Reumatismo. 2015 Mar 31;66(4):304-17. doi: 10.4081/reumatismo.2014.798. Reumatismo. 2015. PMID: 25829190 Free article. Review.

Cite

Share

4

Cite

Share

Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study.

Zerbinati N, Esposito C, D'Este E, Calligaro A, Valsecchi R. Zerbinati N, et al. Among authors: calligaro a. Dermatol Ther (Heidelb). 2018 Mar;8(1):101-110. doi: 10.1007/s13555-018-0226-5. Epub 2018 Feb 13. Dermatol Ther (Heidelb). 2018. PMID: 29442292 Free PMC article.

Cite

Share

5

Cite

Share

Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block.

Ruffatti A, Favaro M, Brucato A, Ramoni V, Facchinetti M, Tonello M, Del Ross T, Calligaro A, Hoxha A, Grava C, De Silvestro G. Ruffatti A, et al. Among authors: calligaro a. Transfus Apher Sci. 2015 Dec;53(3):269-78. doi: 10.1016/j.transci.2015.11.006. Epub 2015 Nov 25. Transfus Apher Sci. 2015. PMID: 26626966 Review.

Cite

Share

6

Cite

Share

Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study.

Hoxha A, Favaro M, Calligaro A, Del Ross T, Ruffatti AT, Infantolino C, Tonello M, Mattia E, Ruffatti A. Hoxha A, et al. Among authors: calligaro a. Thromb Haemost. 2020 Jan;120(1):36-43. doi: 10.1055/s-0039-1697665. Epub 2019 Oct 21. Thromb Haemost. 2020. PMID: 31634958

Cite

Share

7

Cite

Share

IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers.

Tonello M, Mattia E, Favaro M, Del Ross T, Calligaro A, Salvan E, Hoxha A, Fedrigo M, Ruffatti A. Tonello M, et al. Among authors: calligaro a. Thromb Res. 2019 May;177:157-160. doi: 10.1016/j.thromres.2019.03.006. Epub 2019 Mar 8. Thromb Res. 2019. PMID: 30903876

Cite

Share

8

Cite

Share

The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions.

D'Angelo A, Geroldi D, Hancock MA, Valtulina V, Cornaglia AI, Spencer CA, Emanuele E, Calligaro A, Koschinsky ML, Speziale P, Visai L. D'Angelo A, et al. Among authors: calligaro a. Biochim Biophys Acta. 2005 Feb 21;1687(1-3):1-10. doi: 10.1016/j.bbalip.2004.10.005. Biochim Biophys Acta. 2005. PMID: 15708348

Cite

Share

9

Cite

Share

Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.

Lorenzin M, Ortolan A, Cozzi G, Calligaro A, Favaro M, Del Ross T, Doria A, Ramonda R. Lorenzin M, et al. Among authors: calligaro a. Clin Rheumatol. 2021 Nov;40(11):4569-4580. doi: 10.1007/s10067-021-05799-0. Epub 2021 Jun 16. Clin Rheumatol. 2021. PMID: 34136971 Free PMC article.

Cite

Share

10

Cite

Share

Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome.

Ruffatti A, Tonello M, Macor P, Calligaro A, Del Ross T, Favaro M, Lotti V, Carletto A, Hoxha A, Biasi D. Ruffatti A, et al. Among authors: calligaro a. Blood. 2021 May 27;137(21):2989-2992. doi: 10.1182/blood.2020010575. Blood. 2021. PMID: 33649771 No abstract available.

Cite

Share